Skip Navigation LinksHome > December 2001 - Volume 95 - Issue 6 > Brain Expression of Inducible Cyclooxygenase 2 Messenger RNA...
Anesthesiology:
Laboratory Investigations

Brain Expression of Inducible Cyclooxygenase 2 Messenger RNA in Rats Undergoing Cardiopulmonary Bypass

Hindman, Bradley J. M.D.*; Moore, Steven A. M.D., Ph.D.†; Cutkomp, Johann B.S.‡; Smith, Tom B.S.‡; Ross-Barta, Susan E. M.S.§; Dexter, Franklin M.D., Ph.D.*; Brian, Johnny E. Jr., M.D.*

Free Access
Article Outline
Collapse Box

Author Information

Collapse Box

Abstract

Background : We hypothesized that systemic proinflammatory cytokines or endotoxemia, or both, associated with cardiopulmonary bypass (CPB) would increase expression of inducible cyclooxygenase (COX-2) or inducible nitric oxide synthase (iNOS) messenger RNA (mRNA), or both, in brain.
Methods : Isoflurane-anesthetized Sprague-Dawley rats were randomly selected for CPB (n = 6) or sham surgery (n = 6). All animals underwent tracheotomy and controlled ventilation, arterial and venous pressure monitoring, insertion of a jugular venous outflow catheter, insertion of a subclavian arterial inflow catheter, systemic anticoagulation (500 U/kg heparin) and, except during CPB, servoregulation of pericranial temperature at 37.5°C. Animals selected for CPB underwent 1 h of CPB at 165 ml · kg1 · min1 (31.8 ± 0.2°C), whereas animals having sham surgery underwent no intervention during this interval. Thereafter, all animals were given protamine and remained anesthetized for 4 more h. Brain and liver COX-2 and iNOS mRNA expression were determined by a ribonuclease protection assay with ribosomal L32 mRNA as a loading control. Arterial blood was analyzed for interleukin 1β, interleukin 6, and endotoxin concentrations.
Results : Endotoxin concentrations did not increase above baseline values in either group. At 4 h after the CPB interval, interleukin 6 concentrations were significantly greater in CPB animals (101 ± 45 pg/ml) versus sham animals (44 ± 17 pg/ml) (P = 0.025). Brain COX-2 expression was significantly greater in CPB animals (0.36 ± 0.11) versus shams (0.19 ± 0.08) (P = 0.013). Brain COX-2 expression correlated with interleukin 6 concentration 4 h after CPB (r = 0.91;P = 5 × 105). In brain, iNOS mRNA was not detected in any animal. Cardiopulmonary bypass animals had only trace COX-2 and iNOS mRNA induction in liver.
Conclusions : Cardiopulmonary bypass was associated with increased systemic interleukin 6 concentrations and increased brain COX-2 expression.
CARDIAC surgery conducted with cardiopulmonary bypass (CPB) is associated with increased systemic concentrations of proinflammatory cytokines including interleukins 6 and 8 (IL-6 and IL-8), 1–6 tumor necrosis factor α, 3,6–8 and, in a few studies, interleukin 1β (IL-1β). 5 Endotoxemia is also commonplace during CPB. 2,7–11 Prior studies have focused on the roles of proinflammatory cytokines and endotoxin in adverse cardiopulmonary outcomes after cardiac surgery 2,8,10,12–16 but have not fully considered potential central nervous system sequelae.
In animal sepsis and inflammation models, systemic proinflammatory mediators result in extensive changes in brain gene expression, 17–27 neurochemistry, 28,29 neuroendocrine status, 28,29 thermoregulation, 21,22,29 and cognition 28 and result in behavioral alterations. Both systemic endotoxin 17–21,23,24 and proinflammatory cytokines 22,24 trigger expression of inducible cyclooxygenase (COX-2) 21–24 and inducible nitric oxide synthase (iNOS) 17–20 in the cerebral vasculature 19,21,22,24 or associated perivascular microglia. 20,23,24 Cerebrovascular COX-2 30–32 and iNOS 32,33 expression result in cerebral vasodilation 30,32,33 and increased blood–brain barrier permeability. 31,33 Expression of these genes also modulates the hypothalamic-pituitary-adrenal response to systemic inflammation (fever, adrenocorticotropic hormone and cortisol secretion). 19,26,27
Based on the collective clinical and animal literature, we hypothesized that there would be an association between systemic proinflammatory mediators occurring with CPB (e.g., cytokines or endotoxin) and expression of COX-2 or iNOS messenger RNA (mRNA), or both, within the brain. Although the organ of interest was brain, we measured COX-2 and iNOS expression in liver as well. We selected liver as a comparison organ because it receives portal venous blood (potentially high in endotoxin) and because it is rich in macrophages (Kupffer cells), making it highly responsive to inflammatory stimuli.
Back to Top | Article Outline

Materials and Methods

Experimental protocols were approved by the Animal Care and Use Committee of the University of Iowa in accordance with the “Guide for the Care and Use of Laboratory Animals,” revised in 1996. All surgery was performed under sterile conditions, with particular attention given to avoiding environmental endotoxin contamination. Using computer-generated random numbers and block design, animals were preassigned to one of two groups: surgical shams (n = 6), or CPB (n = 6).
Back to Top | Article Outline
Basic Preparation
Anesthesia was induced in nonfasting male Sprague-Dawley rats (weight, 268–355 g) (Harlan, Indianapolis, IN) by inhalation of isoflurane in room air. Via a midline neck incision, the trachea was cannulated with a 14-gauge intravenous cannula. Animals were ventilated (tidal volume ≈ 15 ml/kg; rate ≈ 40 breaths/min) with ≥1 minimum anesthetic concentration (MAC) of isoflurane (1.5–2.0%) in oxygen. Exhaled gas was monitored continuously with a calibrated anesthetic agent analyzer (Datex; Puritan-Bennet, Helsinki, Finland). A calibrated 22-gauge needle thermistor (Model 552; Yellow Springs Instruments, Yellow Springs, OH) was placed percutaneously into the right temporalis muscle to measure pericranial temperature, which was servoregulated at 37.5°C (Model 73A; Yellow Springs Instruments) using surface warming and cooling.
Via a neck incision, the right external jugular vein was isolated. To serve as a CPB venous outflow cannula, a multiple-orifice catheter (Model PE-200; Intramedic/Becton Dickinson, Sparkes, MD) (OD = 2.0 mm, ID = 1.5 mm, length = 6.5 cm) was inserted into the right external jugular vein, and the tip advanced into the right atrium. Heparinized normal saline, 20 U/ml, was administered at 1 ml/h through this cannula until animals were given large-dose systemic heparin, later in the experiment. Via an axillary incision, the right brachial-subclavian artery was isolated. To serve as a CPB arterial inflow cannula, a 20-gauge intravenous catheter with a tapered 22-gauge tip (OD = 1.1 mm, ID = 0.8 mm, length = 3 cm) was inserted into the brachial artery, and its position adjusted to obtain a nondamped arterial pressure waveform. Via a left groin incision, the femoral artery and vein were cannulated with saline-filled (heparin, 5 U/ml) polyethylene catheters (Model PE-50, Intramedic Becton Dickinson, Sparkes, MD). The femoral arterial catheter was used to record mean arterial pressure and for blood sampling. The femoral venous catheter was used to administer medications and to measure venous pressure. Animals in both groups were then given 500 U/kg heparin and 0.5 mg/kg pancuronium intravenously. The heparin dose was based on pilot studies (n = 5), wherein 500 U/kg heparin increased whole-blood activated clotting time (Hemotec Incorporated, Englewood, CO) from a baseline of 60 ± 10 to 376 ± 108 s. Five minutes after heparin administration, arterial blood was collected for baseline measurement of systemic endotoxin and cytokine concentrations. At the same time, baseline values for mean arterial pressure, venous pressure, pericranial temperature, arterial blood gases (pH, arterial oxygen tension, arterial carbon dioxide tension) (IL1306; Instrumentation Laboratory, Lexington, MA), hemoglobin (OSM3 with rat coefficients; Radiometer, Copenhagen, Denmark), and whole-blood glucose concentration (Model 27; Yellow Springs Instruments) were recorded. Thereafter, animals were managed according to group-specific protocols.
Back to Top | Article Outline
Surgical Sham Protocol
Surgical shams underwent no additional procedures. For the remainder of the experiment (5 h in total), sodium bicarbonate and 10% dextrose in water were given as needed to maintain base excess of −4 mEq/l or greater and glucose concentration of 100 mg/dl or greater, respectively. No blood or blood products were administered at any time. To compensate for repeated blood collection, a modified hetastarch solution was given as needed to maintain venous pressure at baseline values. One hour after baseline measurements, all measurements were repeated. Thereafter, to reverse heparin anticoagulation, 7 mg/kg protamine was administered intravenously. Subclavian artery and jugular venous catheters were flushed with heparinized saline and capped for the remainder of the experiment. Surgical shams remained anesthetized and monitored for another 4 h, at which time a final set of measurements and an activated clotting time were obtained.
Back to Top | Article Outline
Cardiopulmonary Bypass Protocol
After baseline measurements, CPB animals had the jugular and subclavian catheters connected to the CPB circuit and underwent CPB for 1 h. Cardiopulmonary bypass flow rate was maintained constant at 165 ml · kg1 · h1. Normal cardiac output in anesthetized rats is approximately 200 ml · kg−1 · h−1. 34 Complete, or near-complete, CPB was indicated by the absence or near-absence (≤ 5 mmHg) of arterial pulsation measured from the femoral artery catheter. The oxygenator was ventilated with oxygen containing 1.5–2.0% isoflurane. Pulmonary ventilation was continued during CPB with isoflurane,1.5%, in oxygen at a reduced rate and tidal volume (10 ml/kg, 20 breaths/min). Mean arterial pressure, venous pressure, pericranial temperature, blood gas values, and arterial hemoglobin and glucose concentrations were measured every 15 min during CPB. Arterial blood gases were measured at electrode temperatures of 37°C and were not temperature corrected (α-stat method). During CPB, a modified hetastarch mixture was given to maintain venous reservoir volume as needed. For the remainder of the experiment, sodium bicarbonate and 10% dextrose in water were given as needed to maintain base excess of −4 mEq/l or greater and glucose concentration of 100 mg/dl or greater, respectively. During the first 30 min of CPB, animals were allowed to cool passively to 32°C. This was performed to approximate clinical practice. Rewarming was initiated at 30 min of CPB. After 1 h of CPB, but before separation from CPB and protamine, all measurements (endotoxin, cytokines, systemic variables) were repeated. Blood was also collected for activated clotting time measurement. Normal ventilation was restored, and animals were separated from CPB without any inotropic or vasopressor support. Thereafter, to reverse heparin anticoagulation, 7 mg/kg protamine was administered intravenously. After separation from CPB, subclavian and jugular catheters were flushed with heparinized saline and capped. Hemodynamics, temperature, and blood chemistries were measured at least hourly after CPB. Perfusate remaining in the CPB circuit was centrifuged to obtain buffy coat-free erythrocytes. After CPB, these erythrocytes were given to maintain a hemoglobin concentration of 12 g/dl or greater. A modified hetastarch solution was also given to maintain intravascular volume and maintain mean arterial pressure of 80 mmHg or greater. CPB animals remained anesthetized and monitored for 4 h after separation from CPB, at which time a final set of measurements (endotoxin, cytokines, systemic variables, activated clotting time) were obtained.
All CPB circuit components were sterile for each use. The circuit consisted of a venous reservoir (20-ml syringe), a peristaltic pump (Masterflex Model 7523-10; Cole-Parmer, Vernon Hills, IL), and a neonatal hollow-fiber oxygenator with the heat exchanger removed (Micro; Cobe Cardiovascular Incorporated, Arvada, CO), connected by Tygon tubing (size 16; Saint Gobain Plastics, Akron, OH). Except for the oxygenator, all circuit components were new for each use. The oxygenator was reused to reduce cost. After each use, the oxygenator was rinsed with tap water for 2 h, followed by a flush of 4 l sterile water, air dried overnight, and then ethylene oxide gas–sterilized. Before each experiment, the circuit was primed with 50 ml Plasmalyte A (Baxter Healthcare Corporation, Deerfield, IL), circulated for 30 min at 150 ml/min through a 0.2-μm filter. Thereafter, the circuit was drained, refilled with Plasmalyte A, and filtered again. Following this, the filter was removed and the circuit was drained and refilled with 50 ml of a heparinized (5 U/ml) modified hetastarch solution. The modified commercial hetastarch solution had the following composition: 4.8% high-molecular-weight hydroxyethyl starch, Na+ = 141 mEq/l, Cl = 137 mEq/l, K+ = 3.2 mEq/l, HCO3 = 18 mEq/l, Ca2+ = 5.4 mEq/l, Mg2+ = 4.1 mEq/l, glucose = 200 mg/dl.
Approximately 15 min before CPB, 25–30 ml of the modified hetastarch was removed from the circuit and replaced with 25–30 ml of fresh (< 5 min from collection) whole heparinized (10 U/ml) rat blood, collected from two isoflurane-anesthetized donor rats. The final priming mixture of blood and modified hetastarch had a hemoglobin concentration ranging between 7.0 and 8.3 g/dl. Immediately before CPB, a sample of the blood and hetastarch priming mixture was obtained for measurement of hemoglobin concentration, as well as endotoxin and cytokine concentrations. Circuit warming was achieved by use of heat tape, which was wrapped around the oxygenator and reservoir.
Back to Top | Article Outline
End of Experiment
In both groups, after obtaining the final set of systemic measurements (4 h after protamine administration), animals were killed by an intravenous overdose of 390 mg/kg pentobarbital and 50 mg/kg phenytoin (Euthasol®; Delmarva Laboratories, Midlothian, VA). Brain and liver were rapidly removed and frozen on dry ice. Tissue remained frozen at −70°C until assayed for mRNA expression.
Back to Top | Article Outline
Positive Control Animals
To serve as positive control animals for iNOS and COX-2 gene induction, two additional rats were assigned to be given intravenous lipopolysaccharide (LPS), the active moiety of endotoxin. Anesthesia, tracheotomy, mechanical ventilation, temperature monitoring, and femoral arterial and venous catheterization were performed as previously described. These animals did not undergo jugular or brachial arterial cannulation. Animals were given a 2-mg/kg intravenous bolus of LPS (Escherichia coli 055:B5; Sigma Chemical Company, St. Louis, MO), which has been shown to induce both COX-2 and iNOS 18,24 mRNA in rat brain and iNOS mRNA in rat liver. 18 Peak responses to systemic LPS occur 2–6 h after administration. After LPS administration the animals remained anesthetized, ventilated, and monitored for 4 h. Thereafter, they were killed and tissue harvested as previously described.
Back to Top | Article Outline
Endotoxin Assay
Endotoxin was assayed using the limulus amebocyte lysate method with chromogenic substrate (QCL-100; BioWhitaker, Inc., Walkersville, MD). All tubes used for collection, processing, and assay of endotoxin were endotoxin free. Arterial blood samples of 300 μl were centrifuged immediately after collection, and plasma was immediately stored at −70°C until assay. All endotoxin assays were run in duplicate. To inactivate nonspecific inhibitors of the limulus amebocyte lysate reaction, 250 μl endotoxin-free water was added to 50-μl samples of thawed plasma and the mixture incubated at 60°C for 30 min. Fifty microliters of limulus amebocyte lysate was added to 50 μl of the diluted, heat-treated sample. The mixture was incubated at 37°C for 10 min. Thereafter, 100 μl of chromogenic substrate was added, and the mixture was vortexed and incubated at 37°C for 30 min. The reaction was stopped with 800 μl of stop solution provided by the manufacturer. Absorbance (optical density) was measured at 410 nm using a spectrophotometer. To correct for nonspecific absorbance, for each sample a “blank” was prepared exactly as just described, except 50 μl of endotoxin-free water was substituted for 50 μl limulus amebocyte lysate. Sample absorbance was calculated as the mean of two sample measurements minus the absorbance of the corresponding sample blank. Standard absorption curves (410 nm) were prepared with known concentrations of standard endotoxin supplied with the kit. The endotoxin standard has a potency of approximately 1 endotoxin activity unit (EU) per 100 pg of endotoxin (0.01 EU/ml ≈ 1 pg/ml). Control assays indicated that neither heparin (≤ 10 IU/ml) nor hetastarch had any effect on the endotoxin assay. The minimum detection level was 0.01 EU/ml.
Back to Top | Article Outline
Cytokine Assays
We decided to measure IL-1β and IL-6. Although an increase in IL-1β has been detected in only a few CPB studies, IL-1β has been shown to induce both COX-2 22,24 and iNOS mRNA in brain. 35 Interleukin 6 was selected because it is uniformly reported to be increased after CPB and because systemic IL-6 has been shown to mediate a host of central nervous system responses.
Arterial blood samples of 400 μl were collected into tubes containing trisodium EDTA, with a final EDTA concentration of 1.5 mg/ml. Blood samples were centrifuged immediately after collection, and plasma was immediately stored at −70°C until assay. Assays were performed using commercial rat-specific ELISA kits (BioSource International Inc., Camarillo, CA) in exact accordance with manufacturer’s instructions. To eliminate interassay variation, cytokine analyses were performed “in batch” in such a manner that, for each cytokine, all samples were assayed on a single ELISA plate. For IL-1β the minimal detection level was 3 pg/ml, with an intraassay coefficient of variation of 8%. For IL-6 the minimal detection level was 8 pg/ml, with an intraassay coefficient of variation of 4%. Any individual measured value for cytokine concentration that was less than the minimal detection level for the assay was recorded as zero.
Back to Top | Article Outline
Ribonuclease Protection Assays
Ribonuclease protection assays to quantitate of COX-2, iNOS, and RPL32-4A (“L32”) mRNA were performed as previously described. 36,37 The L32 mRNA codes for a constitutively expressed ribosomal protein, which is not affected by inflammatory stimuli and thereby serves as an internal loading control. Accordingly, COX-2 and iNOS mRNA expression was quantitated relative to L32 mRNA expression. Murine complementary DNA fragments for COX-2, iNOS, and L32 in pGEM plasmids were generous gifts of Iain L. Campbell, Ph.D. (The Scripps Research Institute, La Jolla, CA). The expected protected fragment sizes are 300 base pairs (bp) for COX-2, 275 bp for iNOS, and 80 bp for L32. The ability of these probes to detect rat COX-2 and iNOS transcripts was previously established using an LPS- and cytokine-activated rat alveolar cell line, NR8383 (American Type Culture Collection, Manassas, VA).
Liver and brain were thawed on ice and homogenized in ice-cold RNA-STAT 60 (Tel-Test Incorporated, Friendswood, TX). Total RNA was isolated following the manufacturer’s instructions. For the synthesis of a 32P-radiolabeled antisense RNA probe, equimolar mixtures of linear COX-2, iNOS, and L32 templates were used. Hybridization reactions were performed overnight at 56°C. After ribonuclease digestion, RNA duplexes were isolated by electrophoresis in a standard sequencing gel of 7.5% acrylamide, 12 m urea, and 0.5% Tris-boric acid-EDTA. Dried gels were placed on BioMax MR film (Eastman Kodak Company, Rochester NY) and were exposed at −70°C. Band intensity was quantitated by densitometry. To eliminate interassay variation, these assays were performed in batch in such a manner that each assay, which incorporated all samples, was performed on a single gel. In our laboratory, the intraassay coefficient of variation of COX-2/L32 and iNOS/L32 ratios ranges between 2 and 12%.
Back to Top | Article Outline
Statistical Analysis
Data are reported as mean ± SD. Between-group comparisons of arterial IL-6 concentration and brain COX-2 mRNA expression were performed using Student t test with separate variances (SYSTAT version 9.0 for Windows; SPSS, Chicago, IL). The correlation between IL-6 and brain COX-2 mRNA was assessed using the Pearson correlation. P values were interpreted using the Hochberg method to correct for multiple comparisons. The overall α for the three statistical comparisons was less than 0.05.
Back to Top | Article Outline

Results

Systemic Variables
Table 1
Table 1
Image Tools
Systemic variables are summarized in table 1. At baseline, sham and CPB groups were equivalent in all measured variables. During the CPB interval, CPB animals had lesser values for mean arterial pressure, hemoglobin concentration, and pericranial temperature than sham animals, which is consistent with clinical CPB. There were no hypotensive reactions to protamine in any animal. In the 4 h after protamine administration, sham and CPB animals did not differ with respect to mean arterial pressure, venous pressure, pericranial temperature, arterial pH, partial pressure of oxygen (Po2), partial pressure of carbon dioxide (Pco2), or blood glucose. The CPB animals tended to be given more bicarbonate (3.4 ± 0.9 vs. 1.3 ± 0.3 ml), glucose (4.3 ± 4.3 vs. 0.2 ± 0.4 ml), modified hetastarch (1.3 ± 1.3 vs. 0.8 ± 1.6 ml), and packed erythrocytes (4.7 ± 1.3 vs. 0 ± 0 ml) than sham animals. Although not intended, CPB animals had greater final (4-h) values for hemoglobin than did sham animals.
Before CPB, the CPB priming mixture contained IL-1β, IL-6, and endotoxin at concentrations that were not greater than baseline in vivo values. Therefore, CPB animals were not given large doses of exogenous endotoxin, IL-1β, or IL-6. At the end of the CPB interval (before protamine administration), systemic IL-1β, IL-6, and endotoxin concentrations did not differ from baseline values in either group, nor did they differ between groups. Four hours after the CPB interval, IL-1β and endotoxin concentrations did not differ from baseline values, nor did they differ between groups. In contrast, at 4 h after the CPB interval, systemic IL-6 concentrations were greater than baseline in both groups and were significantly greater in CPB animals than in sham animals (101 ± 45 vs. 44 ± 17 pg/ml, respectively;P = 0.025).
Back to Top | Article Outline
Gene Expression
Table 2
Table 2
Image Tools
Fig. 1
Fig. 1
Image Tools
Gene expression is summarized in table 2. In brain, COX-2 mRNA expression was significantly greater in CPB animals versus sham animals; COX-2/L32 ratios were 0.36 ± 0.11 versus 0.19 ± 0.11, respectively (P = 0.013). As shown in figure 1, there was a significant correlation between brain COX-2 mRNA expression and systemic IL-6 concentrations measured 4 h after the CPB interval (r = 0.91;P = 5 × 105). There was no discernible correlation between systemic endotoxin concentration and either systemic IL-6 concentration or brain COX-2 mRNA expression. Brain iNOS mRNA expression was not detected in any sham or CPB animal.
In liver, CPB animals exhibited extremely weak COX-2 mRNA expression (COX-2/L32 ratio = 0.06 ± 0.04), which was discernibly greater than that of sham animals, which showed no liver COX-2 mRNA expression at all (COX-2/L32 ratio = 0 ± 0). Likewise, CPB animals also exhibited extremely weak liver iNOS mRNA expression (iNOS/L32 ratio = 0.06 ± 0.06), which was, again, discernibly greater than that of sham animals, which showed no liver iNOS mRNA expression at all (iNOS/L32 ratio = 0 ± 0).
In the positive control animals (LPS animals), there was robust brain COX-2 mRNA expression (COX-2/L32 ratios of 0.98 and 1.04 respectively) and robust liver iNOS expression (iNOS/L32 ratios of 15.42 and 11.23 respectively). In these two animals, liver COX-2/L32 ratios were 0 and 0.87, and contrary to expectation, brain iNOS mRNA was not detected.
Back to Top | Article Outline

Discussion

Overview of Findings and Clinical Implications
Neurologic and neurocognitive abnormalities are common after cardiac surgery and CPB and are associated with greater intensive care unit and hospital length of stay, greater mortality, greater need for rehabilitative care, 38 and long-term cognitive dysfunction. 39 Despite intensive investigation, the mechanisms underlying neurocognitive abnormalities after CPB remain incompletely understood and therapies intended to prevent these complications have often failed. 40 In part, progress has been hampered because of the lack of a suitable survival animal model of CPB. 40 Because (1) brain physiology and pathophysiology are well characterized in the rat, (2) rats can be readily separated from CPB and survive for extended periods, 41 and (3) preliminary results indicate that neurologic dysfunction after CPB is present in rats, 41 this model holds promise for characterization of CPB-associated brain injury.
In the current experiment, systemic concentrations of proinflammatory cytokines and endotoxin in CPB animals were generally less than expected. In CPB animals, systemic IL-1β and endotoxin concentrations were not significantly greater than baseline values at any time, nor did they differ from values obtained from sham animals. The vast majority of CPB studies have not observed increases in IL-1β. In contrast, endotoxemia (generally in the range of 20–40 pg/ml) is commonly observed. 2,7–11 Therefore, in CPB animals the absence of a detectable IL-1β response was expected, but the absence of endotoxemia was not. Interleukin 6 concentrations did not differ between groups after the 1-h CPB interval but were significantly greater in CPB animals versus sham animals 4 h later. This is consistent with prior studies which showed that IL-6 concentrations do not increase during CPB but, instead, peak 2–6 h afterward. 1,5–7,12,13,42 In the current experiment, IL-6 concentrations after CPB (101 ± 45 pg/ml) were twofold to fourfold less than generally reported after human cardiac surgery and CPB. 1,2,4–6,12,42 Despite relatively low levels of systemic proinflammatory mediators, brain COX-2 mRNA expression in CPB animals was twofold greater than in sham animals and was approximately one third as great as that of rats given a potent stimulus for brain COX-2 induction (LPS). There was a significant correlation between systemic IL-6 concentrations and brain COX-2 expression, which suggests an interaction between systemic and brain inflammatory responses to CPB.
We propose that systemic IL-6 or brain COX-2 induction, or both, could be responsible for some of the commonly observed abnormalities in cerebral physiology after CPB, such as fever, 14,43 blood–brain barrier dysfunction, 44,45 and, perhaps, acute abnormalities in neurologic status or cognition as well. 46 We base this proposal on the following observations. In animals, systemic IL-6 results in fever, 47 increased blood–brain barrier permeabilty, 48 and altered neurotransmitter balance 49 and behavior. 50 In mice, IL-6 mediates the constellation of “sickness behaviors” (fever, anorexia, cachexia, and lethargy) that occur in response to noninfectious tissue injury and inflammation. 51 In animals, cerebrovascular COX-2 induction has been shown to mediate neuroendocrine (cortisol) and thermoregulatory (fever) responses to systemic proinflammatory mediators 26,27 and to result in increased blood–brain barrier permeabilty 31 and cerebral vasodilation. 30,32 In humans, administration of IL-6 results in fever, headache, myalgia, malaise, nausea, 52,53 cortisol secretion, 54 and, at high doses, transient neurologic abnormalities. 52 In the setting of cardiac surgery, IL-6 concentration after CPB has been shown to correlate with both postoperative fever 13 and S-100β concentration after CPB. 1 S-100β is a glial protein that gains access to the systemic circulation when blood–brain barrier permeability is increased. 55 The association between IL-6 and S-100β suggests that IL-6 might increase blood–brain barrier permeability directly or, perhaps, by inducing cerebrovascular COX-2.
Back to Top | Article Outline
Features and Limitations of This Experiment
The current experiment is largely exploratory and clearly is not definitive. We did not demonstrate an association between brain COX-2 induction and any neurologic or neurophysiologic abnormality. Nevertheless, the experiment does make three new observations: (1) like humans, rats exhibit a systemic inflammatory response (albeit mild) after clinically analogous CPB, (2) brain inflammatory gene induction occurs after CPB, and (3) there may be an interaction between these two responses.
COX-2 mRNA is constitutively expressed in some neurons in the amygdala, hippocampus, hypothalamus, and neocortex. 21,23,24 Therefore, some “background” COX-2 mRNA expression in sham animals was expected. In rats, brain COX-2 mRNA has been shown to be most strongly induced by systemic endotoxin, but systemic IL-1β, tumor necrosis factor α, and even noninfectious peripheral tissue inflammation can, to lesser extent, also induce cerebrovascular COX-2 mRNA. 24 Given the short half-lives of IL-1 and endotoxin (minutes), it is possible that transient increases of these proinflammatory mediators could have occurred in the current experiment without detection.
Although there was a significant correlation between systemic IL-6 concentration and brain COX-2 mRNA expression, such an association does not necessarily imply causation. Indeed, prior rat studies indicate that IL-6 alone does not induce brain COX-2. 24,25 This suggests either (1) that the process (or mediator) which led to increased systemic IL-6 production in CPB animals proportionally coinduced brain COX-2 or (2) that increased brain COX-2 mRNA expression after CPB is augmented by systemic IL-6. Support for the latter possibility comes from experiments showing activation of the hypothalamic-pituitary-adrenal axis and that induction of brain c-fos mRNA in response to IL-1β or LPS varies proportionally with plasma IL-6 level. 56 Therefore, in some circumstances, systemic IL-6 modulates the central nervous system effects of other proinflammatory stimuli. 57,58
The CPB animals differed from sham animals in that they had 1 h of mild systemic hypotension, anemia, and hypothermia. This was performed to reproduce conditions common during clinical CPB. Although mean arterial pressure during CPB was greater than the lower limit of cerebral autoregulation in rats (50–60 mmHg), 59 both hemodilution 60 and hypothermia 61 can impair cerebral autoregulatory responses. Both animal 62 and human 63 studies have indicated that global cerebral oxygenation is adequately maintained under clinical CPB conditions. Nevertheless, we cannot rule out the possibility that CPB animals may have had some degree of mild cerebral ischemia during CPB. Transient cerebral ischemia, even when insufficient to result in neuronal necrosis, can rapidly increase brain COX-2 mRNA expression. 64 Therefore, in the current experiment, it is possible that brain COX-2 induction might have been triggered by ischemia, with subsequent modulation by systemic IL-6. However, even if brain COX-2 induction were to be triggered on an ischemic rather than on an inflammatory basis, this does not alter the potential central nervous system sequelae of brain COX-2 induction.
Systemic IL-6 peaks 2–6 h after all forms of surgery and roughly corresponds to the overall magnitude of tissue injury. 65 In the setting of cardiac surgery, the heart 3,42,66 and, perhaps, the lungs 15 are major contributors to the increase of IL-6 after CPB, producing IL-6 in response to temporary ischemia. In the current experiment, the heart was continuously perfused and beating, hypotension during CPB was moderate, and we observed no signs of myocardial dysfunction whatsoever after CPB. Although the lungs of CPB animals had low pulmonary artery flow for 1 h and, in rats, ischemia of this duration can result in lung injury, 67 there was no evidence of overt pulmonary dysfunction after CPB. Therefore, in the current experiment, neither heart nor lung would seem likely as a major source of IL-6 production. This may in part explain why IL-6 levels after CPB were less than generally observed in clinical studies.
Greater IL-6 levels have been observed in patients who were given allogenic red blood cells during or shortly after CPB versus patients who were not. 68 Because all CPB animals were exposed to donor red cells, whereas sham animals were not, greater IL-6 levels in CPB animals could have been on this basis. However, in separate pilot experiments, rats undergoing exchange transfusions with the CPB priming mixture (95 ml/kg whole heparinized rat blood and hetastarch; n = 6) did not differ from sham animals (n = 6) in systemic IL-6 levels or brain COX-2 mRNA expression 4 h later (unpublished data available on request from Brad Hindman, M.D., Associate Professor of Anesthesia, University of Iowa, College of Medicine, Iowa City, Iowa, August, 1999).
Both animal 69 and human 70 studies have indicated that splanchnic perfusion is often unfavorably affected by CPB, and indications of gut mucosal ischemia are commonly present. Probably on this basis, CPB increases gut permeabilty, 9,16 allowing endotoxin from resident flora access to the portal and then systemic circulation. 9 Therefore, it is possible that gut-associated macrophages, producing IL-6 in response to translocated endotoxin, could have been the source of increased IL-6 in CPB animals. 71 Although we did not observe a significant increase in systemic endotoxin in CPB animals, the liver has a huge capacity to clear endotoxin originating from the portal circulation. 72 We observed an extremely small increase in COX-2 and iNOS mRNA expression in the livers of CPB animals, approximately 200 and 14 times less than the respective responses to intravenous LPS. This barely detectable upregulation of liver iNOS and COX-2 expression argues against a significant amount of endotoxin being present in the portal vein of CPB animals and thereby argues against transient undetected systemic endotoxemia as the primary cause of brain COX-2 induction. The apparent absence of endotoxemia in the current experiment suggests that splanchnic perfusion in this rat CPB model is relatively well maintained. Because liver macrophages (Kupffer cells) typically exhibit a robust inflammatory response to systemic inflammatory stimuli, the near-absence of liver iNOS and COX-2 induction is consistent with the possibility that brain COX-2 mRNA induction was facilitated but not directly triggered by systemic IL-6.
In brain, iNOS mRNA was not detected in either sham animals or CPB animals. Unexpectedly, we also did not detect brain iNOS mRNA in our two “positive control animals” that were given LPS. The dose of LPS given to our two positive control animals has been shown to result in brain iNOS mRNA induction in prior studies. 17–20 Although brain iNOS was not detected, animals being given LPS did have a strong liver iNOS mRNA signal. Therefore, the iNOS probe used in the current experiment appropriately binds and protects rat iNOS mRNA during the ribonuclease digestion phase of the assay. Prior studies demonstrating brain iNOS induc-tion after LPS used either in situ hybridization 19,20 or polymerase chain reaction gene amplification techniques. 17,18 Both techniques are extremely sensitive. Furthermore, these studies show that endotoxin-mediated brain iNOS mRNA induction, although pronounced, is limited to discrete anatomic regions and cell populations. Because we measured whole-brain iNOS mRNA expression, it is possible that iNOS induction in a relatively small number of cells would go undetected with our methodology. An alternative explanation for the absence of brain iNOS mRNA expression, even in the positive control animals, may relate to our use of isoflurane anesthesia. All studies demonstrating brain iNOS induction after LPS administration were performed in animals that were not anesthetized. 17–20 In a murine macrophage-like cell line, clinically relevant concentrations (1 minimum anesthetic concentration) of isoflurane have been shown to completely inhibit LPS-induced iNOS mRNA expression. 73 Therefore, in the current experiment, isoflurane anesthesia may have reduced or prevented brain iNOS mRNA expression in response to LPS or CPB-associated proinflammatory stimuli, or both. In summary, we found that four hours after CPB, brain COX-2 mRNA expression was significantly greater in CPB rats versus sham animals and correlated with arterial Il-6 concentration.
Back to Top | Article Outline

References

1. Ashraf S, Bhattacharya K, Tian Y, Watterson K: Cytokine and S100β levels in paediatric patients undergoing corrective cardiac surgery with and without total circulatory arrest. Eur J Cardiothorac Surg 1999; 16: 32–7

2. Cremer J, Martin M, Redl H, Bahrami S, Abraham C, Graeter T, Haverich A, Schlag G, Borst H-G: Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996; 61: 1714–20

3. Wan S, DeSmet J-M, Barvais L, Goldstein M, Vincent J-L, LeClerc J-L: Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996; 112: 806–11

4. Horton SB, Butt WW, Mullaly RJ, Thuys CA, O’Connor EB, Byron K, Cochrane AD, Brizard CP, Karl TR: IL-6 and IL-8 levels after cardiopulmonary bypass are not affected by surface coating. Ann Thorac Surg 1999; 68: 1751–5

5. Nandate K, Vuylsteke A, Crosbie AE, Messahel S, Oduro-Dominah A, Menon DK: Cerebrovascular cytokine responses during coronary bypass surgery: Specific production of interleukin-8 and its attenuation by hypothermic cardiopulmonary bypass. Anesth Analg 1999; 89: 823–8

6. Baufreton C, Intrator L, Jansen PGM, te Velthuis H, Le Besnerais P, Vonk A, Farcet J-P, Wildevuur CRH, Loisance DY: Inflammatory response to cardiopulmonary bypass using roller or centrifugal pumps. Ann Thorac Surg 1999; 67: 972–7

7. Martinez-Pellús AE, Merino P, Bru M, Conejero R, Seller G, Muñoz C, Fuentes T, Gonzalez G, Alvarez B: Can selective digestive decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass? Crit Care Med 1993; 21: 1684–91

8. te Velthuis H, Jansen PGM, Oudemans-van Straaten HM, Sturk A, Eijsman L, Wildevuur CRH: Myocardial performance in elderly patients after cardiopulmonary bypass is suppressed by tumor necrosis factor. J Thorac Cardiovasc Surg 1995; 110: 1663–9

9. Oudemans-van Straaten HM, Jansen PGM, Hoek FJ, van Deventer SJH, Sturk A, Stoutenbeek CP, Tytgat GNJ, Wildevuur CRH, Eysman L: Intestinal permeability, circulating endotoxin, and postoperative systemic responses in cardiac surgery patients. J Cardiothorac Vasc Anesth 1996; 10: 187–94

10. Bowles CT, Ohri SK, Klangsuk N, Keogh Be, Yacoub MH, Taylor KM: Endotoxaemia detected during cardiopulmonary bypass with a modified Limulus amoebocyte lysate assay. Perfusion 1995; 10: 219–28

11. te Velthuis H, Jansen PGM, Oudemans-van Straaten HM, van Kamp GJ, Sturk A, Eijsman L, Wildevuur CRH: Circulating endothelin in cardiac operations: Influence of blood pressure and endotoxin. Ann Thorac Surg 1996; 61: 904–8

12. Deng MC, Dasch B, Erren M, Möllhoff T, Scheld HH: Impact of left ventricular dysfunction on cytokines, hemodynamics, and outcome in bypass grafting. Ann Thorac Surg 1996; 62: 184–90

13. Teoh KHT, Bradley CA, Gauldie J, Burrows H: Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery. Circulation 1995; 92 (suppl 2): 2-347–53

14. Journois D, Israel-Biet D, Pouard P, Rolland B, Silvester W, Vouhé P, Safran D: High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology 1996; 85: 965–76

15. Hauser GJ, Ben-Ari J, Colvin MP, Dalton HJ, Hertzog JH, Bearb M, Hopkins RA, Walker SM: Interleukin-6 levels in serum and lung lavage fluid of children undergoing open heart surgery correlate with postoperative morbidity. Intensive Care Med 1998; 24: 481–6

16. Sinclair DG, Haslam PL, Quinlan GJ, Pepper JR, Evans TW: The effect of cardiopulmonary bypass on intestinal and pulmonary endothelial permeability. Chest 1995; 108: 718–24

17. Satta MA, Jacobs RA, Kaltsas GA, Grossman AB: Endotoxin induces interleukin-1β and nitric oxide synthase mRNA in rat hypothalamus and pituitary. Neuroendocrinology 1998; 67: 109–16

18. Jacobs RA, Satta MA, Dahia PLM, Chew SL, Grossman AB: Induction of nitric oxide synthase and interleukin-1ß, but not heme oxygenase, messenger RNA in rat brain following peripheral administration of endotoxin. Mol Brain Res 1997; 49: 238–46

19. Wong M-L, Rettori V, Al-Shekhlee A, Bongiorno PB, Canteros G, McCann SM, Gold PW, Licinio J: Inducible nitric oxide synthase gene expression in the brain during systemic inflammation. Nature Medicine 1996; 2: 581–4

20. Wong M-L, Bongiorno PB, Al-Shekhlee A, Esposito A, Khatri P, Licinio J: IL-1β, IL-1 receptor type I and iNOS gene expression in rat brain vasculature and perivascular areas. Neuroreport 1996; 7: 2445–8

21. Cao C, Matsumura K, Yamagata K, Watanabe Y: Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response. Brain Res 1995; 697; 187–96

22. Cao C, Matsumura K, Yamagata K, Watanabe Y: Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1β: A possible site of prostaglandin synthesis responsible for fever. Brain Res 1996; 733: 263–72

23. Elmquist JK, Breder CD, Sherin JE, Scammell TE, Hickey WF, Dewitt D, Saper CB: Intravenous lipopolysaccharide induces cyclooxygenase 2-like immunoreactivity in rat brain perivascular microglia and meningeal macrophages. J Comp Neurol 1997; 381: 119–29

24. Lacroix S, Rivest S: Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain. J Neurochem 1998; 70: 452–66

25. Vallières L, Rivest S: Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropin-releasing factor during endotoxemia. Endocrinology 1999; 140: 3890–3903

26. Rivest S: What is the cellular source of prostaglandins in the brain in response to systemic inflammation? Facts and controversies. Mol Psychiatry 1999; 4: 501–7

27. Rivest S, Lacroix S, Vallières L, Nadeau S, Zhang J, LaFlamme N: How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Experimental Biology and Medicine 2000; 223: 22–38

28. Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H: Synergistic effects of interleukin-1α, interleukin-6, and tumor necrosis factor-α: Central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 2000; 22: 566–80

29. Linthorst ACE, Reul JMHM: Brain neurotransmission during peripheral inflammation. Ann N Y Acad Sci 1998; 840; 139–52

30. Brian JE, Moore SA, Faraci FM: Expression and vascular effects of cyclooxygenase-2 in brain. Stroke 1998; 29: 2600–6

31. Tsao N, Hsu H-P, Lei H-Y: TNFα-induced cyclooxygenase 2 not only increases the vasopermeability of blood-brain barrier but also enhances the neutrophil survival in Escherichia coli-induced brain inflammation. Prostaglandins Other Lipid Mediators 1999; 57: 371–82

32. Okamoto H, Ito O, Roman RJ, Hudetz AG: Role of inducible nitric oxide synthase and cyclooxygenase-2 in endotoxin-induced cerebral hyperemia. Stroke 1998; 29: 1209–18

33. Mayhan WG: Effect of lipopolysaccharide on the permeability and reactivity of the cerebral microcirculation: role of inducible nitric oxide synthase. Brain Res 1998; 792: 353–7

34. Carmichael FJ, Crawford MW, Khayyam N, Saldivia V: Effect of propofol infusion on splanchnic hemodynamics and liver oxygen consumption in the rat. Anesthesiology 1993; 79: 1051–60

35. Bonmann E, Suschek C, Spranger M, Kolb-Bachofen V: The dominant role of exogenous or endogenous interleukin-1 beta on expression and activity of inducible nitric oxide synthase in rat microvascular brain endothelial cells. Neurosci Lett 1997; 230: 109–12

36. Chiang C-S, Stalder A, Samimi A, and Campbell IL: Reactive gliosis as a consequence of interleukin-6 expression in the brain: Studies in transgenic mice. Dev Neurosci 1994; 16: 212–21

37. Brian JE Jr., Faraci FM, Moore SA, Ludwig P: COX-2 dependent delayed dilatation of cerebral arterioles in response to bradykinin. Am J Physiol 2001; 280: H2023–9

38. Roach GW, Kanchuger M, Mangano CM, Newman M, Nussmeier N, Wolman R, Aggarwal A, Marschall K, Graham SH, Ley C, Ozanne G, Mangano DT: Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med 1996; 335: 1857–63

39. Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA: Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med 2001; 344: 395–402

40. Hindman BJ, Todd MM: Improving neurologic outcomes after cardiac surgery (editorial). Anesthesiology 1999; 90: 1243–7

41. Grocott HP, Mackensen GB, Newman MF, Warner DS: Neurological injury during cardiopulmonary bypass in the rat. Perfusion 2001; 16: 75–81

42. Fransen E, Maessen J, Dentener M, Senden N, Geskes F, Buurman W: Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest 1998; 113: 1290–5

43. Bissonnette B, Holtby MH, Davis AJ, Pua H, Gilder FJ, Black M: Cerebral hyperthermia in children after cardiopulmonary bypass. Anesthesiology 2000; 93: 611–8

44. Harris DNF, Bailey SM, Smith PLC, Taylor KM, Oatridge A, Bydder G: Brain swelling in first hour after coronary artery bypass surgery. Lancet 1993; 342: 586–7

45. Harris DNF, Oatridge A, Dob D, Smith PLC, Taylor KM, Bydder GM: Cerebral swelling after normothermic cardiopulmonary bypass. Anesthesiology 1998; 88: 340–5

46. Rolfson DB, McElhaney JE, Rockwood K, Finnegan BA, Entwistle LM, Wong JF, Suarez-Almazor ME: Incidence and risk factors for delirium and other adverse outcomes in older adults after coronary artery bypass graft surgery. Can J Cardiol 1999; 15: 771–6

47. Dinarello CA, Cannon JG, Mancilla J, Bishai I, Lees J, Coceani F: Interleukin-6 as an endogenous pyrogen: Induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells. Brain Res 1991; 562: 199–206

48. Saija A, Princi P, Lanza M, Scalese M, Aramnejad E, De Sarro A: Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sci 1995; 56: 775–84

49. Wang J, Dunn AJ: Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem Int 1998; 33: 143–54

50. Zalcman S, Murray L, Dyck DG, Greenberg AH, Nance DM: Interleukin-2 and –6 induce behavioral-activating effects in mice. Brain Res 1998; 811: 111–21

51. Kozak W, Poli V, Soszynski D, Conn CA, Leon LR, Kluger MJ: Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am J Physiol 1999; 272: R621–30

52. Weber J, Gunn H, Yang J, Parkinson D, Topalian S, Schwartzentruber D, Ettinghausen S, Levitt D, Rosenberg SA: A phase I trial of intravenous interluekin-6 in patients with advanced cancer. J Immunother 1994; 15: 292–302

53. Van Gameren MM, Willemse PH, Mulder NH, Limburg PC, Groen HJ, Vellenga E, de Vries EG: Effects of recombinant human interleukin-6 in cancer patients: A phase I-II study. Blood 1994; 85: 1434–41

54. Stouthard JM, Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJ, Veenhof CH, Sauerwein HP: Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 1995; 268: E813–9

55. Büttner T, Weyers S, Postert T, Sprengelmeyer R, Kuhn W: S-100 protein: Serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke 1997; 28: 1961–5

56. Lenczowski MJP, Schmidt ED, Van Dam A-M, Gaykema RPA, Tilders FJH: Individual variation in hypothalamus-pituitary adrenal responsiveness of rats to endotoxin and interleukin-1β. Ann N Y Acad Sci 1998; 856: 139–47

57. Zhou D, Shanks N, Riechman SE, Liang R, Kusnecov AW, Rabin BS: Interleukin 6 modulates interleukin-1 and stress-induced activation of the hypothalamic-pituitary-adrenal axis in male rats. Neuroendocrinology 1996; 63: 227–36

58. Wang J, Dunn AJ: The role of interleukin-6 in the activation of the hypothalamo-pituitary-adrenocortical axis and brain indoleamines by endotoxin and interleukin-1β. Brain Res 1999; 815: 337–48

59. Lee JG, Hudetz AG, Smith JJ, Hillard CJ, Bosnjak ZJ, Kampine JP: The effects of halothane and isoflurane on cerebrocortical microcirculation and autoregulation as assessed by laser-Doppler flowmetry. Anesth Analg 1994; 79: 58–65

60. Maruyama M, Shimoji K, Ichikawa T, Hashiba M, Naito E: The effects of extreme hemodilutions on the autoregulation of cerebral blood flow, electroencephalogram and cerebral metabolic rate of oxygen in the dog. Stroke 1985; 16: 675–9

61. Verhaegen MJJ, Todd MM, Hindman BJ, Warner DS: Cerebral autoregulation during moderate hypothermia in rats. Stroke 1993; 24: 407–14

62. Hindman BJ, Dexter F, Cutkomp J, Smith T, Tinker JH: Hypothermic acid-base management does not affect cerebral metabolic rate for oxygen (CMR o2) at 27°C: A study during cardiopulmonary bypass in rabbits. Anesthesiology 1993; 79: 580–7

63. Patel RL, Turtle MR, Chambers DJ, James DN, Newman S, Venn GE: Alpha-stat acid-base regulation during cardiopulmonary bypass improves neuropsychologic outcome in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1996; 111: 1267–79

64. Planas AM, Soriano MA, Justicia C, Rodríguez-Farré E: Induction of cyclooxygenase-2 in the rat brain after a mild episode of focal ischemia without tissue inflammation or neural cell damage. Neurosci Let 1999; 275: 141–4

65. Reber PU, Andrén-Sandberg Å, Schmied B, Büchler MW: Cytokines in surgical trauma: Cholecystectomy as an example. Dig Surg 1998; 15: 92–101

66. Dreyer WJ, Phillips SC, Lindsey ML, Jackson P, Bowles NE, Michael LH, Entman ML: Interleukin 6 induction in the canine myocardium after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2000; 120: 256–63

67. Steimle CN, Guynn TP, Morganroth ML, Bolling SF, Carr K, Deeb GM: Neutrophils are not necessary for ischemia-reperfusion lung injury. Ann Thorac Surg 1992; 53: 64–73

68. Fransen E, Maessen J, Dentener M, Senden N, Buurman W: Impact of blood transfusion on inflammatory mediator release in patients undergoing cardiac surgery. Chest 1999; 116: 1233–9

69. Tao W, Zwischenberger JB, Nguyen TT, Vertrees RA, McDaniel LB, Nutt LK, Herndon DN, Kramer GC: Gut mucosal ischemia during normothermic cardiopulmonary bypass results from blood flow redistribution and increased oxygen demand. J Thorac Cardiovasc Surg 1995; 110: 819–28.

70. McNicol L, Andersen LW, Liu G, Doolan L, Baek L: Markers of splanchnic perfusion and intestinal translocation of endotoxins during cardiopulmonary bypass: Effects of dopamine and milrinone. J Cardiothorac Vasc Anesth 1999; 13: 292–8

71. Deitch EA, Xu D, Franko L, Ayala A, Chaudry IH: Evidence favoring the role of the gut as a cytokine-generating organ in rats subjected to hemorrhagic shock. Shock 1994; 1: 141–6

72. Jiang J, Bahrami S, Leichtfried G, Redl H, Öhlinger W, Schlag G: Kinetics of endotoxin and tumor necrosis factor appearance in portal and systemic circulation after hemorrhagic shock in rats. Ann Surg 1995; 221: 100–6

73. Tschaikowsky K, Ritter J, Schröppel K, Kühn M: Volatile anesthetics differentially affect immunostimulated expression of inducible nitric oxide synthase: Role of intracellular calcium. Anesthesiology 2000; 92: 1093–102

Cited By:

This article has been cited 20 time(s).

Journal of Cardiothoracic and Vascular Anesthesia
Con: Methylprednisolone is not indicated for patients during cardiopulmonary bypass
Sulzer, CF; Mackensen, GB; Grocott, HP
Journal of Cardiothoracic and Vascular Anesthesia, 19(2): 255-258.
10.1053/j.jvca.2005.02.008
CrossRef
Frontiers in Bioscience
Vascular changes after cardiac surgery: role of NOS, COX, kinases, and growth factors
Sodha, NR; Clements, RT; Sellke, FW
Frontiers in Bioscience, 14(): 689-698.
10.2741/3273
CrossRef
Heart Surgery Forum
Emboli, inflammation, and CNS impairment: An overview
Hindman, BJ
Heart Surgery Forum, 5(3): 249-253.

Anaesthesist
Non-opioid analgesics for perioperative pain therapy. Risks and rational basis for application
Brack, A; Rittner, HL; Schafer, M
Anaesthesist, 53(3): 263-280.
10.1004/s00101-003-0641-5
CrossRef
Chest
Postoperative cognitive dysfunction after cardiac surgery
Gao, L; Taha, R; Gauvin, D; Othmen, LB; Wang, Y; Blaise, G
Chest, 128(5): 3664-3670.

Life Sciences
Cardiopulmonary bypass and long-term neurocognitive dysfunction in the rat
Dieleman, JM; de Lange, F; Houston, RJF; Biessels, GJ; Bar, PR; Mackensen, GB; Grocott, HP; Kalkman, CJ
Life Sciences, 79(6): 551-558.
10.1016/j.lfs.2006.01.036
CrossRef
Journal of Cardiothoracic and Vascular Anesthesia
Cardiopulmonary bypass reduces the minimum alveolar concentration for isoflurane
Yang, H; Homi, HM; Smith, BE; Grocott, HP
Journal of Cardiothoracic and Vascular Anesthesia, 18(5): 620-623.
10.1053/j.jvca.2004.07.001
CrossRef
Anesthesia and Analgesia
Hippocampus bcl-2 and bax expression and neuronal apoptosis after moderate hypothermic cardiopulmonary bypass in rats
Zhang, TJ; Hang, J; Wen, DX; Hang, YN; Sieber, FE
Anesthesia and Analgesia, 102(4): 1018-1025.
10.1213/01.ane.0000199221.96250.8c
CrossRef
Perfusion-Uk
Long-term assessment of NF kappa B expression in the brain and neurologic outcome following deep hypothermic circulatory arrest in rats
Kellermann, K; Gordan, ML; Nollert, G; Blobner, M; Kochs, EF; Jungwirth, B
Perfusion-Uk, 24(6): 429-436.
10.1177/0267659109358655
CrossRef
Annals of Thoracic Surgery
Brain injury and neuropsychological outcome after coronary artery surgery are affected by complement activation
Baufreton, C; Allain, P; Chevailler, A; Etcharry-Bouyx, F; Corbeau, JJ; Legall, D; de Brux, JL
Annals of Thoracic Surgery, 79(5): 1597-1605.
10.1016/j.athoracsur.2004.08.061
CrossRef
Journal of Thoracic and Cardiovascular Surgery
Cerebral tumor necrosis factor alpha expression and long-term neurocognitive performance after cardiopulmonary bypass in rats
Jungwirth, B; Kellermann, K; Qing, M; Mackensen, GB; Blobner, M; Kochs, EF
Journal of Thoracic and Cardiovascular Surgery, 138(4): 1002-1007.
10.1016/j.jtcvs.2009.06.022
CrossRef
Journal of Thoracic and Cardiovascular Surgery
Increased cerebral and renal endothelial nitric oxide synthase gene expression after cardiopulmonary bypass in the rat
Mazer, CD; Briet, F; Blight, KR; Stewart, DJ; Robb, M; Wang, ZL; Harrington, AM; Mak, W; Li, XM; Hare, GMT
Journal of Thoracic and Cardiovascular Surgery, 133(1): 13-U50.
10.1016/j.jtcvs.2006.06.047
CrossRef
Journal of Anesthesia
Neuroprotection during cardiac surgery
Grocott, HP; Yoshitani, K
Journal of Anesthesia, 21(3): 367-377.
10.1007/s00540-007-0514-1
CrossRef
Anesthesia and Analgesia
The Impact of Cardiopulmonary Bypass on Systemic Interleukin-6 Release, Cerebral Nuclear Factor-kappa B Expression, and Neurocognitive Outcome in Rats
Jungwirth, B; Eckel, B; Blobner, M; Kellermann, K; Kochs, EF; Mackensen, GB
Anesthesia and Analgesia, 110(2): 312-320.
10.1213/ANE.0b013e3181bbc42e
CrossRef
Journal of Cardiothoracic and Vascular Anesthesia
Xenon and the inflammatory response to cardiopulmonary bypass in the rat
Clark, JA; Ma, DQ; Homi, HM; Maze, M; Grocott, HP
Journal of Cardiothoracic and Vascular Anesthesia, 19(4): 488-493.
10.1053/j.jvca.2005.05.007
CrossRef
Anesthesia and Analgesia
Differential cerebral gene expression during cardiopulmonary bypass in the rat: Evidence for apoptosis?
Sato, Y; Laskowitz, DT; Bennett, ER; Newman, MF; Warner, DS; Grocott, HP
Anesthesia and Analgesia, 94(6): 1389-1394.

British Journal of Clinical Pharmacology
The efficacy of parecoxib on systemic inflammatory response associated with cardiopulmonary bypass during cardiac surgery
Wu, QP; Purusram, G; Wang, HQ; Yuan, RX; Xie, WL; Gui, P; Dong, NG; Yao, SL
British Journal of Clinical Pharmacology, 75(3): 769-778.
10.1111/j.1365-2125.2012.04393.x
CrossRef
Anesthesiology
Xenon Attenuates Cardiopulmonary Bypass–induced Neurologic and Neurocognitive Dysfunction in the Rat
Ma, D; Yang, H; Lynch, J; Franks, NP; Maze, M; Grocott, HP
Anesthesiology, 98(3): 690-698.

PDF (1494)
Anesthesiology
The Systemic Inflammatory Response to Cardiac Surgery: Implications for the Anesthesiologist
Warltier, DC; Laffey, JG; Boylan, JF; Cheng, DC
Anesthesiology, 97(1): 215-252.

PDF (640)
Anesthesia and Analgesia
Hemodilution during cardiopulmonary bypass increases cerebral infarct volume after middle cerebral artery occlusion in rats
Homi, HM; Yang, H; Pearlstein, RD; Grocott, HP
Anesthesia and Analgesia, 99(4): 974-981.
10.1213/01.ane.0000131504.90754.d0
CrossRef
Back to Top | Article Outline

© 2001 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.
Login

Article Tools

Images

Share